Jupiter Topco LLC Makes New $1.51 Million Investment in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Jupiter Topco LLC bought 15,500 Dianthus Therapeutics shares worth approximately $1.51 million in the second quarter. Institutional investors now own 47.53% of DNTH, including a new $194.96 million position from ABS Investment Management.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $126.92. Recent targets range from $122 to $158, though Weiss Ratings reiterated a sell rating.
• Insiders have sold approximately $29.67 million worth of shares over the past three months, including major sales by the CEO and a director. Dianthus reported a quarterly loss of $0.90 per share, missing estimates, while revenue of $0.76 million exceeded expectations.

Jupiter Topco LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,500 shares of the company's stock, valued at approximately $1,511,000.

Several other hedge funds also recently modified their holdings of DNTH. ABS Investment Management LLC acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at about $194,960,000. PNC Financial Services Group Inc. boosted its stake in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company's stock worth $3,135,000 after buying an additional 139 shares in the last quarter. First Horizon Corp acquired a new position in shares of Dianthus Therapeutics in the 1st quarter valued at $32,000. Virtus Investment Advisers LLC boosted its position in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company's stock valued at $260,000 after acquiring an additional 416 shares in the last quarter. Finally, EFG International AG bought a new stake in Dianthus Therapeutics in the second quarter valued at about $49,000. 47.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Wedbush lifted their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. HC Wainwright boosted their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Citigroup assumed coverage on shares of Dianthus Therapeutics in a report on Friday. They issued a "buy" rating and a $156.00 target price on the stock. Finally, Truist Financial lifted their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $126.92.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Anne McGeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the transaction, the director owned 1,250 shares of the company's stock, valued at approximately $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares of the company's stock, valued at $7,058,718.12. This trade represents a 71.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 283,678 shares of company stock worth $29,672,400 over the last three months. Company insiders own 3.02% of the company's stock.

Dianthus Therapeutics Price Performance

DNTH opened at $108.10 on Friday. Dianthus Therapeutics, Inc. has a one year low of $24.49 and a one year high of $117.88. The stock has a market capitalization of $5.91 billion, a P/E ratio of -26.05 and a beta of 1.24. The company's 50 day simple moving average is $105.23 and its 200-day simple moving average is $89.08.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.